Hasil Pencarian - H. Kantarjian

Perbaiki Hasil
  1. 1
    Highly Reproducible Detection and Semi-Quantification of Telomerase Activity

    Highly Reproducible Detection and Semi-Quantification of Telomerase Activity oleh S. Verstovsek, T. Manshouri, H. Kantarjian, F.J. Giles, M. Keating, E. Estey, M. Albitar

    Diterbitkan 2001-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML

    P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML oleh A. Bidikian, H. Kantarjian, E. Jabbour, N. Short, F. Ravandi, G. Issa, K. Sasaki

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER

    P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER oleh L. Masarova, P. Bose, N. Pemmaraju, H. Chifotides, L. Zhou, Z. Estrov, H. Kantarjian, S. Verstovsek

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS

    P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS oleh S. P. Desikan, G. Montalban-Bravo, M. Ohanian, N. Daver, T. Kadia, S. Venugopal, K. Chien, H. Kantarjian, G. Garcia-Manero

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN

    P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGI... oleh T. Abuasab, J. Senapati, T. Kadia, F. Ravandi, C. DiNardo, N. Pemmaraju, M. Ohanion, Y. Alvarado, H. Kantarjian, G. Borthakur

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS

    P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS oleh J. Senapati, S. Verstovsek, L. Masarova, N. Pemmaraju, G. Montalban Bravo, S. Pierce, L. Zhou, G. Garcia-Manero, H. Kantarjian, P. Bose

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML

    P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML oleh J. Senapati, F. Haddad, F. Ravandi, T. Kadia, C. DiNardo, N. Daver, N. Pemmaraju, Y. Alvarado, M. A. Brandt, H. Kantarjian, G. Borthakur

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS

    P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS oleh F. Haddad, H. Kantarjian, E. Jabbour, N. Short, A. Bidikian, J. Ning, L. Xiao, N. Pemmaraju, K. Marx, F. Ravandi, K. Sasaki, G. Issa

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY

    PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PH... oleh E. Jabbour, G. Martinelli, M. Vignetti, H. Kantarjian, D. Gomez-Almaguer, Y. Minami, H. Dombret, M. Hennessy, A. Vorog, B. Wang, J.-M. Ribera

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES

    P1066: OUTCOMES OF COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS - AN OBSERVATIONAL COHORT STUDY FROM A LARGE ACADEMIC CANCER CENTER IN THE UNITED STATES oleh S. Venugopal, H. Song, C. Young, M. A. Cutherell, J. A. Baganz, S. Zatorsky, S. E. Woodman, N. Pemmaraju, P. Bose, L. Masarova, L. Zhou, S. Pierce, H. Kantarjian, S. Verstovsek

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)

    PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34) oleh F. Ong, T. M. Kadia, N. J. Short, M. Yilmaz, Y. Alvarado, S. Pierce, G. Garcia-Manero, C. DiNardo, G. Borthakur, M. Konopleva, N. Daver, H. Kantarjian, F. Ravandi

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL

    S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL oleh G. Montalban-Bravo, F. Ma, I. Ganan-Gomez, R. Kanagal-Shamana, V. Adema, N. Thongon, H. Yang, K. A. Soltysiak, C. Bueso-Ramos, H. Kantarjian, G. Garcia-Manero, S. Colla

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)

    P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) oleh T. Kadia, F. Ravandi, G. Borthakur, E. Jabbour, G. Montalban-Bravo, L. Adewale, S. Pierce, C. Lacke, M. Brandt, N. Short, N. Jain, J. Burger, A. Ferrajoli, W. Wierda, H. Kantarjian

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

    P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC L... oleh S. Venugopal, H. kantarjian, A. Maiti, N. Short, G. Montalban-Bravo, Y. Alvarado, K. S. Chien, R. Kanagal-Shamanna, N. Pemmaraju, N. Daver, T. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME

    P769: MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME oleh K. Kim, K. Chien, O. Faustine, G. Montalban-Bravo, R. Kanagal-Shamanna, T. Kadia, E. Jabbour, Y. Alvarado, K. Sasaki, X. Q. Dong, S. Pierce, C. Bueso-Ramos, H. Kantarjian, G. Garcia-Manero

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA

    P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEM... oleh A. Bazinet, T. Kadia, N. Short, G. Borthakur, S. Wang, S. Loghavi, J. Jorgensen, K. Patel, C. DiNardo, N. Daver, Y. Alvarado, F. Haddad, S. Pierce, M. Andreeff, E. Jabbour, M. Konopleva, H. Kantarjian, F. Ravandi

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB

    P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB oleh W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, K. Sasaki, P. Kebriaei, M. Yilmaz, P. Thompson, K. Takahashi, H. Abbas, W. Wierda, R. Garris, H. Kantarjian, N. Short

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

    P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES oleh K. Chien, K. Kim, Z. Li, R. Kanagal Shamanna, F. Ong, G. Montalban Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS

    P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS oleh S. Venugopal, E. Jabbour, N. Pemmaraju, G. Montalban-Bravo, K. S. Chien, N. Daver, N. Jain, J. Burger, Y. Alvarado, A. Maiti, C. D. DiNardo, G. Borthakur, R. Malla, G. Garcia-Manero, F. Ravandi, H. Kantarjian, T. Kadia

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE

    P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE oleh K. Kim, F. Ong, Z. Li, R. Kanagal-Shamanna, G. Montalban-Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero, K. Chien

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: